End-of-day quote
Other stock markets
|
||
- USD | - |
03-26 | GT Biopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
02-01 | GT Biopharma to Conduct 1-for-30 Reverse Stock Split; Shares Fall | MT |
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 4.14M 5.7M |
---|---|---|---|---|---|
Net income 2024 * | -17M -23.4M | Net income 2025 * | - | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-0.28
x | P/E ratio 2025 * |
-
| Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 83.75% |
Managers | Title | Age | Since |
---|---|---|---|
Michael Breen
CEO | Chief Executive Officer | 62 | 21-01-12 |
Manu Ohri
DFI | Director of Finance/CFO | 67 | 22-02-17 |
Jeffrey Miller
PRN | Corporate Officer/Principal | - | 22-12-13 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 78 | 23-04-30 | |
Bruce Wendel
BRD | Director/Board Member | 70 | 20-11-10 |
Rajesh Shrotriya
BRD | Director/Board Member | 79 | 21-01-12 |
1st Jan change | Capi. | |
---|---|---|
+34.00% | 704B | |
+27.15% | 577B | |
-7.75% | 348B | |
+18.53% | 327B | |
+4.95% | 288B | |
+14.91% | 234B | |
+4.93% | 198B | |
-9.78% | 194B | |
-4.89% | 147B |